Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

secure logo.png

SECURE is a long-term prospective observational study sponsored by Oxford University Hospitals NHS Foundation Trust and funded by Cancer Research UK and the National Institutes for Health Research.

The study aims to find out more about the role of family history and demographic factors in the development of MGUS, a pre-cursor to Myeloma, which occurs in approximately 3.2% of people aged 50 and over. Only a small proportion of these people – around 1% each year - will develop myeloma. 

Earlier diagnosis of myeloma might be possible with better understanding MGUS and how it should be monitored. The SECURE study will help with this. It will help confirm the rate at which people with MGUS progress to a diagnosis of myeloma and further our understanding of screening, diagnosis, and monitoring patterns of people with MGUS in the UK. It will also find out more about the psychological impact of an MGUS diagnosis and individual quality of life.

Patients with MGUS are identified by their clinical care team and invited to participate in the SECURE study. Participants are asked to provide blood samples and answer questionnaires annually for a period of 5 years or until their disease changes. It will recruit approximately 2000 people from 20 NHS sites in the UK.

For more information and to get involved in SECURE, please contact the central study team at


magneto logo.png

MAGNETO is an exciting phase I pilot study, sponsored by Oxford University Hospitals NHS Foundation Trust and funded by GlaxoSmithKline. This study is investigating whether a new type of imaging scan can be used to assess patients with Myeloma. The scan involves injecting patients with a small dose of a radioactive antibody (radiotracer) 89Zr-belantamab. The radiotracer is made from a drug that is used to treat myeloma. It is expected to selectively accumulate in the cancer and measured using a PET scanner. 

In this study, patients who have myeloma detectable by other types of imaging scan will be recruited. Up to 19 patients will be injected with the radiotracer twice and scanned up to 12 times over the course of 14-21 days to help determine to which degree and how quickly the radiotracer accumulates in the myeloma tumours. This is useful as, whilst not therapeutic, it will help understand the best time for imaging patients and also give an indication of how much radiation the patients are exposed to by the test.